Ceftobiprole is a cephalosporin that effectively treats bacteremia caused by Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus. Recently, a study published in the international journal New England Journal of Medicine entitled "Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia " in the international journal New England Journal of Medicine, scientists from Duke University's Center for Health Research and other institutions have found that an antibiotic that is highly effective against bacterial pneumonia may be able to successfully fight off infections caused by methicillin-resistant Staphylococcus aureus.
The drug, called cefepime, showed similar therapeutic effects to the antibiotic daptomycin in treating complicated S. aureus infections, and if approved by the FDA, cefepime may provide another line of protection against a common and deadly bacterial infection. Thomas Holland, M.D., says this may be an area of real research, as there hasn't been a new antibiotic developed for S. aureus bacteremia in more than 15 years.
In the study, called ERADICATE, researchers enrolled 390 patients with complicated Staphylococcus aureus infections at 60 sites in 17 countries from August 2018 through March 2022, with about half of the patients randomly assigned to receive an infusion of cefepime while the other half received daptomycin intravenously. The primary treatment outcome for the patients was the overall therapy outcome, which might entail removing surviving bacteria from the bloodstream, prompting improvement in the patient's organic disease symptoms and no complications from bacterial infections for 70 days post-treatment, while patient safety should also be evaluated.
The researchers found that both antibiotics had similar treatment outcomes, with 69.8 percent of patients in the cefepime treatment group experiencing overall success with the treatment, compared to only 68.7 percent in the daptomycin group, that both drugs were similarly tolerated, and that gastrointestinal problems in patients were the most common side effect. The researchers stated that despite their current work in the field of medical science research, complicated S. aureus infections can still cause a patient mortality rate of up to 25% within 90 days, so they currently need more options to treat these infections.
In summary, the results of this paper suggest that the antibiotic cefepime may have similar therapeutic efficacy as daptomycin in terms of overall treatment success in patients with complicated S. aureus bacteremia.
